1 July 2021 in Journal of Clinical Neonatology
Aim: The aim of this study is to evaluate the predictive value of routine cranial ultrasonography in preterm infants under 32 weeks' gestation with their neuromotor outcome at 2 years. Methods: This was a prospective, single-center, cohort study of preterm infants under 32 weeks' gestation. Each infant had an early (within 1 week of birth) and late (at 6 weeks postnatal age) cranial ultrasound scan performed. Each infant's scan result was independently assessed for the presence of major cranial abnormalities, such as intraventricular hemorrhage Grade 3 or 4, cystic periventricular leukomalacia, and porencephalic cyst. All surviving infants who returned for follow-up at 2 years' corrected age had their neuromotor development assessed using the Bayley Scales of Infant Development. The predictive value of major cranial abnormalities for the neuromotor delay was derived. Results: A total of 134 infants were included over 2 year. Of the 89 children with no major abnormality, 78 did not have a significant neuromotor delay, giving a negative predictive value of 87.6%. Of the six children with major abnormalities, two had a significant neuromotor delay, giving a positive predictive value of 33.3%. Conclusions: The absence of a major abnormality on quality-controlled routine cranial ultrasound scan in preterm infants under 32 weeks' gestation appears to be a good predictor of no significant abnormality in neuromotor development at 2 years of age.
1 April 2025 in Indian Pediatrics
10 November 2026 in Journal of Pediatric Gastroenterology and Nutrition
Objective: To determine the impact of powdered human milk‐based fortification (PHMF) compared to powdered bovine milk‐based fortification on gut microbiome and inflammation in preterm infants. Methods: Mechanistic study within randomised controlled trial in infants <32 weeks gestation or <1500 g birthweight, only receiving human milk and fully enterally fed without previous fortification, in two UK neonatal intensive care units (NICU). Stool and urine at recruitment (D0), weekly until day 21 (D21) and discharge. Microbiota (stool) and secretory immunoglobulin A (sIgA)/IgA (stool and urine) were evaluated at all time points and immune related proteins (IRP) (stool) at day 7 (D7) and D21. Results: Twenty‐eight patients (14 per arm; median gestation 27.18 ± 2.42 weeks) participated. One hundred and twenty‐nine stools and 109 urines were collected. Analysis of gut microbiota (111 stools), sIgA (113 stools and 108 urines), and IRPs (52 stools) was performed. Fortifier type did not significantly impact stool alpha or beta diversity or specific taxa and explained <5% of variance at any time point, with site being most influential (14.7% at day 14 [D14], p = 0.04; 25.7% at D21, p = 0.007). Stool but not urine sIgA was higher in PHMF recipients. Whilst fortifier type was not associated with IRPs from D7 to D21, NICU site impacted IRPs. Conclusions: Fortifier type did not have a large impact on microbiota or IRPs but stool sIgA was higher in PHMF recipients. An association between NICU site and other outcomes was observed. Trial Registration: ClinicalTrials.gov identifier: The Preterm milk fortification in neonates (PUFFIN) study was prospectively registered ISRCTN 22484792.
1 February 2020 in Pediatric Medicine
Hypoxic ischaemic encephalopathy (HIE) is a devastating illness that has long lasting impact on families as well as staff members. There are a number of national projects that are currently being undertaken to reduce the incidence of HIE, still births and early neonatal deaths due to complications during labour and delivery. Most of these projects involve a systematic review of all the circumstances leading on to the final event including the key members of the team who can bring all the documented and un-documented concerns and viewpoints to the table. This includes a sincere collaboration amongst obstetricians and neonatologists. As results of such a systematic analysis, a number of key factors come into light which may potentially lead on to either the event causing HIE or may be able to prevent the severe outcome. In this talk, Dr. Garg will go through the whole process and how the learning points have been implemented into the practice.